Supernus Pharmaceuticals (SUPN) Return on Invested Capital (2020 - 2025)

Supernus Pharmaceuticals (SUPN) has 6 years of Return on Invested Capital data on file, last reported at 0.01% in Q4 2025.

• On a quarterly basis, Return on Invested Capital fell 1.0% year-over-year to 0.01% in Q4 2025; TTM through Dec 2025 was 0.01%, a 1.0% decrease from a year earlier, with the FY2025 full-year figure at 0.01%, down 2.0% from the prior year.
• Return on Invested Capital for Q4 2025 stood at 0.01%, down from 0.0% in the prior quarter.
• Over the last five years, Return on Invested Capital for SUPN reached as high as 0.01% in Q1 2021 and fell as low as 0.01% in Q4 2025.
• Historically, Return on Invested Capital has averaged 0.0% across 5 years, with a median of 0.0% in 2022.
• Across the five-year window, Return on Invested Capital fell 1 bps in 2021 and changed 0 bps in 2022, its largest moves.
• Year by year, Return on Invested Capital stood at 0.01% in 2021, then slumped by 51 bps to 0.0% in 2022, then tumbled by 105 bps to 0.0% in 2023, then surged by 2387 bps to 0.0% in 2024, then slumped by 292 bps to 0.01% in 2025.
• Per Business Quant data, the three most recent Return on Invested Capital figures were 0.01% in Q4 2025, 0.0% in Q3 2025, and 0.0% in Q2 2025.